Adjuvant Nivolumab vs Ipilimumab

Source: The ASCO Post, ESMO Virtual Congress 2020

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected stage III/IV melanoma (Abstract 1076O).

READ THE ORIGINAL FULL ARTICLE